73 patients), damage and its components one year following diagnosis and at death, disease activity (ECLAM) at diagnosis, components of the metabolic syndrome, smoking and immunosuppressive treatment. Frequencies were compared using the chi-square and Fisher’s exact test, and continuous variables using the t-test and Mann-Whitney U-test. Variables associated with ND were included in a multivariate logistic regression model.

Results We identified 44/90 ND +patients: 17/44 with CIMP, 6/44 with seizures, 21/44 with CA, 20/44 with neuropathy, none with TM. ND +patients had a higher cumulative count of ACR criteria compared to their ND- counterparts (6.02 ±1.23 vs 5.39±1.26). They had a higher proportion of neurologic disorder (NRL-D) (6/37 vs 0/36) and a lower proportion of serositis (4/37 vs 11/36) at diagnosis, as well as higher cumulative proportions of NRL-D (9/44 vs 2/46), hemato logic disorder (41/44 vs 34/46) and lymphopenia (34/44 vs 24/46) (p<0.05). ND +patients also had higher cumulative damage (6.43±3.13 vs 3.43±2.54), higher cumulative proportions of pulmonary (14/44 vs 6/46) and musculoskeletal damage (MSKD) (32/44 vs 21/44), and higher proportions of arterial hypertension (40/44 vs 34/46), secondary sicca (17/44 vs 9/44) (p=0.00001), which were more frequent in patients without JA. There were no significant differences in age, sex or race, but the duration of disease was higher in JA patients (190 vs 118.2 months, p=0.0299). There were significant differences in the presence of malar rash (p=0.0009), photosensitivity (p=0.0032) and pericarditis (p=0.0003), which were more frequent in patients without JA, but arthritis, nephritis, pleuritis, seizures, psychosis, Raynaud’s phenomenon and antiphospholipid syndrome had a similar distribution between both groups. Among the immunological features, no significant difference was found in relation to hemolytic anaemia, lymphopenia, thrombocytopenia, ANA, anti-ENA, anti-DNA, anticardiolipin, anti-β2 glycoprotein I and lupus anticoagulant, but leukopenia was also more frequent in patients without JA (p=0.0041).

Conclusions Serositis may be associated with a lower likelihood of ND, while NRL-D was present at diagnosis only in patients that accrued ND. The association between MSKD and ND requires further elucidation.

Abstract PS8:165 Figure 1

PS8:166 COMPARISON OF CLINICAL AND SEROLOGICAL CHARACTERISTICS BETWEEN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WITH AND WITHOUT ASSOCIATED JACCoud’S ARTHROPATHY

L Villalobos Sánchez, A Aliña Jiménez, A García Fernández, WA Sifuentes Giraldo, MJ García Villanueva, M Vázquez Díaz, A Zea Mendoza. Department of Rheumatology, Ramón y Cajal University Hospital, Madrid, Spain

10.1136/lupus-2018-abstract.209

Objective To compare the profile of clinical and serological manifestations of patients with SLE with and without JA followed in a tertiary care hospital of Madrid.

Methods We performed a retrospective observational study of a cohort of patients diagnosed with SLE (4 or more ACR criteria) between June 1977 and December 2015. The variables evaluated included demographics, clinical, analytical and radiological manifestations. The definition of JA was based on the presence of clinical criteria (reversible joint deformities) and absence of radiographic erosions typical of rheumatoid arthritis.

Results We included 108 patients representing a sample of 24% of the total number of patients with SLE treated at our centre during that period. The majority of patients were women (89.8%), mean age at diagnosis was 30±12.29 years (range: 7–75) and duration of disease was 127 months (range: 2–411). Thirteen patients (12.03%) had findings compatible with JA. There were no significant differences in age, sex or race, but the duration of disease was higher in JA patients (190 vs 118.2 months, p=0.0299). There were significant differences in relation to clinical and serological findings in patients with SLE with JA with respect to those who do not present it.

Abstracts

PS8:167 THERAPEUTIC EFFICACY OF BELIMUMAB IN ADDITION TO STANDARD THERAPY FOR LUPUS NEPHRITIS AND NEUROPSYCHIATRIC LUPUS – CASE SERIES OF ROUTINELY COLLECTED DATA AT A SINGLE CENTRE

J-G. Rademacher, LE Schrempf, M Plüß, GA Müller, P Korsten. University Medical Centre Goettingen, Department of Nephrology and Rheumatology, Goettingen, Germany

10.1136/lupus-2018-abstract.210

Purpose Belimumab (BEL) is approved for Systemic Lupus erythematosus in addition to standard immunosuppressive therapies. Clinical studies have excluded patients with particular organ manifestations from participation in most clinical trials. Most importantly, Lupus nephritis (LN) and neuropsychiatric Systemic Lupus erythematosus (NPSLE) were exclusion criteria in the relevant clinical studies. We aim to report our experience of BEL’s effect on SLE manifestations which have not been formally addressed in clinical trials.

Methods We performed an observational study of routinely collected clinical data of all patients receiving BEL with or without other immunosuppressive therapy at our institution.